VMware, Inc (NYSE:VMW) COO Carl M. Eschenbach unloaded 5,897 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $95.05, for a total value of $560,509.85. Following the sale, the chief operating officer now directly owns 81,879 shares of the company’s stock, valued at approximately $7,782,599. VMware, Inc. (NYSE:VMW) stock performance was 1.54% in last session and finished the day at $96.44. Traded volume was 1.40million shares in the last session and the average volume of the stock remained 2.18million shares. The beta of the stock remained 1.30. VMware, Inc. (NYSE:VMW) insider ownership is 0.20%.

Honeywell International Inc (NYSE:HON) recently launched a campus-wide energy retrofit project for Coe College in Cedar Rapids, IA, for $3.45 million to help the college achieve its energy efficiency targets. The college will fund the project with a loan issued by the Iowa Economic Development Authority (IEDA), which helps colleges by providing funds for energy improvements. Honeywell International Inc. (NYSE:HON) rose 0.21 percent to $91.45 Thursday on volume of 2.38million shares. The intra-day range of the stock was $91.00 to $91.73. Honeywell International Inc. (NYSE:HON) has a market capitalization of $71.62billion.

AbbVie Inc (NYSE:ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including patients with cirrhosis. “This latest regulatory submission is yet another significant achievement for AbbVie’s HCV development program,” said Felipe Pastrana, General Manager, AbbVie Canada. AbbVie Inc (NYSE:ABBV)’s stock on May 22, 2014 reported a increase of 0.68% to the closing price of $53.63. Its fifty two weeks range is $40.10 -$54.78. The total market capitalization recorded $85.28billion. The overall volume in the last trading session was 4.49million shares. In its share capital, ABBV has 1.59billion outstanding shares.

Japanese companies have a history of paying grossly inflated prices for U.S. assets, but the drug maker Eisai would have to be monumentally stupid — and financially reckless — to buy out its obesity drug partner Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). On Thursday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -0.79% to close the day at $6.25. Company return on investment (ROI) is -13.90% and its monthly performance is recorded as 1.46%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is -9.68%.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares jump 2% to $6.48. The company presented at the UBS Global Healthcare Conference being held in New York. Harvey J. Berger, M.D., chairman and chief executive officer, provided overview of company’s business on May 20, 2014, at 4:00 p.m. (ET). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -0.16% in last session and finished the day at $6.34. Traded volume was 6.38million shares in the last session and the average volume of the stock remained 11.20million shares. The beta of the stock remained 1.45. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) insider ownership is 1.80%.